Efficacy and Safety of Mirabegron Compared to Solifenacin in Treatment of Non-neurogenic Overactive Bladder in Children: A Randomized Controlled Trial

Overview

Journal Int Braz J Urol

Date 2025 Feb 6

PMID 39913092

Authors

Islam Mansour

Mahmoud Laymon

Ahmed Abdelhalim

Mohamed S Dawaba

Ahmed S El-Hefnawy

Affiliations

Soon will be listed here.

Abstract

Purpose: Non-neurogenic overactive bladder (OAB) is a common problem in children. Antimuscarinics have been widely used as first-line medical treatment. However, their frequent side effects necessitate searching for therapeutic alternatives. We aimed to assess the efficacy and safety of the beta 3 agonist, mirabegron.

Materials And Methods: A randomized controlled trial enrolled child with non-neurogenic OAB refractory to behavioral urotherapy. Patients were randomized to receive either Mirabegron 25/50 mg based on a 40-kg body weight cutoff or solifenacin 5 mg for 12 weeks. Patients were assessed using Dysfunctional Voiding Scoring System questionnaire (DVSS), 3-day voiding diary and uroflowmetry. Vital signs and adverse effects were recorded at baseline and follow-up. The study primary endpoint was ≥50% reduction of the baseline DVSS.

Results: Among 128 patients screened, 72 patients (36 in each group) completed the study with a mean age of 9.2±2.3 years. Both groups had significant improvement of DVSS and voiding diary (p<0.001) at 12 weeks. In mirabegron group, 94.4% (34/36) had greater than 50% improvement of DVSS compared to 75% (27/36) of solifenacin group (P=0.02). Complete symptom resolution was observed in 22.2% (8/36) patients on mirabegron versus 8.3% (3/36) on solifenacin (P=0.1). Patients on mirabegron had less adverse effects (19.4% vs 47.2%; p=0.01).

Conclusion: Mirabegron is more effective with fewer adverse effects than solifenacin for treatment of children with OAB. Mirabegron treatment improves daytime symptoms and nocturnal enuresis with less risk of constipation. It may be considered as first-line pharmacotherapy in this patient population.

Citing Articles

The New Visual Erection Hardness Score is the Topic Highligheted in this Issue of International Brazilian Journal of Urology.

Favorito L Int Braz J Urol. 2025; 51(2).

PMID: 39913088 PMC: 11884632. DOI: 10.1590/S1677-5538.IBJU.2025.02.01.

References

Tan D, Weninger J, Goyal A . Mirabegron in Overactive Bladder and Its Role in Exit Strategy After Botulinum Toxin Treatment in Children. Front Pediatr. 2022; 9:801517. PMC: 8894583. DOI: 10.3389/fped.2021.801517. View

Vaz G, Vasconcelos M, Oliveira E, Ferreira A, Magalhaes P, Silva F . Prevalence of lower urinary tract symptoms in school-age children. Pediatr Nephrol. 2011; 27(4):597-603. DOI: 10.1007/s00467-011-2028-1. View

Ayan S, Topsakal K, Gokce G, Gultekin E . Efficacy of combined anticholinergic treatment and behavioral modification as a first line treatment for nonneurogenic and nonanatomical voiding dysfunction in children: a randomized controlled trial. J Urol. 2007; 177(6):2325-8. DOI: 10.1016/j.juro.2007.02.001. View

Farhat W, Bagli D, Capolicchio G, OReilly S, Merguerian P, Khoury A . The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. J Urol. 2000; 164(3 Pt 2):1011-5. DOI: 10.1097/00005392-200009020-00023. View

Zoeir A, Gameel T, Hagras A, Uthman A, Fouad A, Moussa A . Translational and linguistic validation of the Arabic version of dysfunctional voiding symptom score questionnaire. J Pediatr Urol. 2023; 19(4):366.e1-366.e6. DOI: 10.1016/j.jpurol.2022.03.025. View

Bael A, Lax H, de Jong T, Hoebeke P, Nijman R, Sixt R . The relevance of urodynamic studies for Urge syndrome and dysfunctional voiding: a multicenter controlled trial in children. J Urol. 2008; 180(4):1486-93. DOI: 10.1016/j.juro.2008.06.054. View

Franck H, Guedes A, Alvim Y, de Andrade T, Oliveira L, Silva L . One-day voiding diary in the evaluation of Lower Urinary Tract Symptoms in children. Int Braz J Urol. 2022; 49(1):89-96. PMC: 9881818. DOI: 10.1590/S1677-5538.IBJU.2022.0375. View

Morin F, Blais A, Nadeau G, Moore K, Genois L, Bolduc S . Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. J Urol. 2016; 197(4):1158-1163. DOI: 10.1016/j.juro.2016.11.101. View

Painter C, Suskind A . Advances in pharmacotherapy for the treatment of overactive bladder. Curr Bladder Dysfunct Rep. 2020; 14(4):377-384. PMC: 7732142. DOI: 10.1007/s11884-019-00562-3. View

10.

Fryer S, Nicoara C, Dobson E, Griffiths M, McAndrew H, Kenny S . Effectiveness and tolerability of mirabegron in children with overactive bladder: A retrospective pilot study. J Pediatr Surg. 2019; 55(2):316-318. DOI: 10.1016/j.jpedsurg.2019.10.044. View

11.

Blais A, Nadeau G, Moore K, Genois L, Bolduc S . Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Eur Urol. 2016; 70(1):9-13. DOI: 10.1016/j.eururo.2016.02.007. View

12.

Weber M, Chapple C, Gratzke C, Herschorn S, Robinson D, Frankel J . A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial. Blood Press Monit. 2018; 23(3):153-163. PMC: 5959217. DOI: 10.1097/MBP.0000000000000320. View

13.

Rittig S, Baka-Ostrowska M, Tondel C, Walle J, Kjaeer B, Passier P . The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. J Pediatr Urol. 2019; 16(1):31.e1-31.e10. DOI: 10.1016/j.jpurol.2019.10.009. View

14.

Marcelissen T, Rashid T, Antunes Lopes T, Barry Delongchamps N, Geavlete B, Rieken M . Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?. Eur Urol Focus. 2018; 5(6):1112-1119. DOI: 10.1016/j.euf.2018.03.011. View

15.

Noh J, Lee B, Kim J . Efficacy and safety of anticholinergics for children or adolescents with idiopathic overactive bladder: systematic review and meta-analysis. Int Urol Nephrol. 2019; 51(9):1459-1471. DOI: 10.1007/s11255-019-02209-y. View

16.

Raman G, Tunnicliffe D, Lai E, Bennett T, Caldwell P . Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review. J Pediatr Urol. 2022; 19(1):19.e1-19.e13. DOI: 10.1016/j.jpurol.2022.09.014. View

17.

Balachandran A, Duckett J . The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder. Eur J Obstet Gynecol Reprod Biol. 2015; 187:60-3. DOI: 10.1016/j.ejogrb.2015.02.020. View

18.

He W, Huang G, Cui W, Tian Y, Sun Q, Zhao X . Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. Int Braz J Urol. 2023; 49(5):535-563. PMC: 10482468. DOI: 10.1590/S1677-5538.IBJU.2023.0158. View

19.

Flynn J, Kaelber D, Baker-Smith C, Blowey D, Carroll A, Daniels S . Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017; 140(3). DOI: 10.1542/peds.2017-1904. View

20.

Sampaio C, Sousa A, Fraga L, Veiga M, Bastos Netto J, Barroso Jr U . Constipation and Lower Urinary Tract Dysfunction in Children and Adolescents: A Population-Based Study. Front Pediatr. 2016; 4:101. PMC: 5046079. DOI: 10.3389/fped.2016.00101. View